"Official medicines" is the best online drugstore.World’s leading meds delivered to your door – and you don’t even need a prescription! Only certified, first class drugs on offer! Buy more and spend less with our great discount system. The meds you need, reliable and hassle free! Top products of top brands.The only pharmacy shop you will ever need! Approved drugs available without prescription. Best deals, unmatched service and shipping. 100% safe! |
| Starlix |
| Class: Antidiabetic |
Action Lowers blood glucose levels by stimulating insulin secretion from the pancreas.
Indications As monotherapy to lower blood glucose in patients with type 2 diabetes mellitus (noninsulin dependent diabetes mellitus) whose hyperglycemia cannot be adequately controlled by diet and exercise and who have not been chronically treated with other antidiabetic agents; in combination with metformin, but not substituted for metformin, in patients whose hyperglycemia is not adequately controlled with metformin alone.
Contraindications Type 1 diabetes; diabetic ketoacidosis.
ADULTS: PO 120 mg tid, 1 to 30 min before meals, alone or in combination with metformin. The 60 mg dose of nateglinide may be used, alone or in combination with metformin, in patients near goal glycosylated hemoglobin when treatment is initiated.
Monoamine oxidase inhibitors, nonselective beta-adrenergic blocking agents, nonsteroidal anti-inflammatory drugs, salicylates: May potentiate the hypoglycemic effects of nateglinide. Corticosteroids, sympathomimetics, thiazide diuretics, thyroid products: May reduce the hypoglycemic effects of nateglinide.
Lab Test Interferences Uric acid levels may be increased.
CNS: Dizziness. GI: Diarrhea. META: Hypoglycemia. RESPIRATORY: Upper respiratory infection; bronchitis; coughing. OTHER: Back pain; flu symptoms; arthropathy; accidental trauma.
Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Hepatic impairment: Use with caution in patients with moderate-to-severe or chronic liver disease. Secondary failure: Transient loss of glycemic control may occur in patients with fever, infection, trauma, or surgery. Special populations: Patients with type 2 diabetes and renal failure on dialysis may exhibit reduced overall drug exposure.
| PATIENT CARE CONSIDERATIONS |
|
|
||||
Popularity: 1% [?]
RSS feed for comments on this post · TrackBack URI
Leave a reply